Question explored with the scientific record
Conversation so far
- 1 Stem cell treatments for Multiple
- 2 Stem cell treatments for Multiple Sclerosis patients Is it successful and safe
- 3 How do I know if my MS is a good fit for aHSCT?
Answered on this page ↓
How do I know if my MS is a good fit for aHSCT?
The short version: aHSCT fits best when your MS is actively inflammatory and still relapsing, and you are young enough and healthy enough to survive the chemo.
The strongest predictor is disease type. The trials that produced the real outcomes enrolled relapsing-remitting MS, not progressive disease: the Swedish cohort was 85% RRMS [2], and the biomarker study was entirely RRMS [3]. In the pooled 764 patients, 68% had no disease activity at 5 years and 23.3% progressed [1]. That is the number you are buying, and it was earned mostly in relapsing patients.
The risk side is the chemo, not the stem cells. Treatment-related death was 5.3% overall, 0.3% after 2005, and 0% with low-intensity regimens [1]. The regimen matters as much as the patient: BEAM plus ATG was the lower-toxicity, recommended approach [2]. A center that runs high-intensity conditioning on a patient who could get a gentler regimen is taking risk it does not need to.
| Factor | What the evidence shows |
|---|---|
| Relapsing-remitting MS | Where the benefit was measured [2][3] |
| Progressive MS | Not the enrolled population in these cohorts [2] |
| Regimen intensity | Low-intensity: 0% treatment death [1] |
| Center experience | Emphasized as a requirement [2] |
| Baseline biomarkers | Did not predict who relapsed after [3] |
One honest limit: no retrieved study tells you which individual will benefit. Baseline spinal fluid markers did not predict post-transplant disease activity [3]. So the decision rests on disease type, activity, regimen, and center, not on a lab test.
My call: a good fit means relapsing MS with active inflammation, a low-intensity regimen at an experienced center, and a body that can take the chemo. Progressive, stable disease is a poor fit on this evidence. Confidence: moderate.
Sources used 3
-
Autologous hematopoietic stem cell transplantation for MS
This study evaluates the safety and efficacy of autologous hematopoietic stem cell transplantation (aHSCT) for multiple sclerosis (MS), suggesting it may be safer and as effective as current disease-modifying drugs.
DOI: 10.1212/WNL.0000000000003995 -
Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis
An expert commentary reviewing the progress, mechanisms, regimens, and clinical implications of autologous hematopoietic stem cell transplantation (AHSCT) for multiple sclerosis, highlighting potential suppression of CNS inflammation and possible disability reversal alongside th…
DOI: 10.1080/1744666X.2017.1297232 -
Biomarkers of progressive multiple sclerosis decrease following autologous hematopoietic stem cell transplantation
In RRMS, AHSCT was associated with sustained reductions in CSF Gal-9 and YKL-40 and a modest early reduction in GDF-15, but baseline biomarker levels did not significantly predict post-AHSCT disease activity.
DOI: 10.1186/s12974-025-03511-6